1. Bio-Techne launched its next-gen Leo™ System for advanced protein analysis. 2. The system increases multiplexing capability to 24 targets per sample. 3. Leo System improves data throughput, efficiency, and precision in research. 4. It strengthens Bio-Techne's market leadership in proteomic analytical instruments. 5. Bio-Techne generated over $1.2 billion in net sales in fiscal 2025.
FAQ
Why Bullish?
The launch of innovative technology typically stimulates investor interest and market confidence. Historical launches of similar products in the biotech sector have often led to increased stock prices.
How important is it?
The advancements in the Leo system will likely increase demand for Bio-Techne's products, drawing in more clients and boosting future revenues. Market innovations often resonate positively, attracting potential investors.
Why Long Term?
As the Leo system is adopted in clinical settings, it may enhance sales and earnings in the long run. Similar product launches in the past have shown significant performance improvements over multiple quarters.
Related Companies
Bio-Techne Unveils Enhanced Leo™ System for Advanced Protein Analysis
Bio-Techne Corporation (NASDAQ: TECH), a leading provider of life science tools and reagents, has announced the launch of its next-generation Leo™ System. This advanced system, powered by Simple Western™ Technology, aims to revolutionize protein analysis by delivering high-throughput capabilities and improved multiplexing functionalities.
Key Features of the Enhanced Leo™ System
The upgraded Leo System integrates chemiluminescence detection with dual-channel fluorescence in the near-infrared (NIR) and infrared (IR) ranges. This combination significantly enhances multiplexing capacity, enabling researchers to examine up to 24 targets per sample. The system is designed to handle complex assay configurations, providing unprecedented flexibility in experimental setups.
- Multiplexing Capabilities: Adds a fourth multiplexing option alongside molecular weight separation, RePlex, and resampling.
- High Throughput: Can process up to 100 capillaries within three hours.
- Precision Results: Achieves 5-6% variability for highly precise quantitative outcomes.
Implications for Clinical Research
The enhanced capabilities of the Leo System represent a significant advancement in clinical research requiring absolute quantitation. Alexandre Lucas, Ph.D., Founder and Manager of We-Met at the French National Institute of Health and Medical Research (INSERM), stated, “Leo represents the future of clinical research requiring absolute quantitation. We chose Leo for its high-throughput capabilities and are consistently achieving highly precise results.”
Will Geist, President of the Protein Sciences Segment at Bio-Techne, emphasized the system's ability to set a new standard in protein analysis: “With advanced detection technologies and built-in compliance features, Leo enables researchers to achieve faster, more reliable results, accelerate critical discoveries, and streamline development timelines.”
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is recognized globally for its innovative life science tools and bioactive reagents, serving research and clinical diagnostic communities. The company plays a vital role in facilitating scientific investigations into biological processes and disease progress. With a portfolio boasting hundreds of thousands of products, Bio-Techne reported over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people worldwide.
For further details about Bio-Techne, visit bio-techne.com or follow them on social media at LinkedIn, X, or YouTube.
Contact Information
For media inquiries, please reach out to:
- Corporate Communications: [email protected]
- David Clair, Vice President: Investor Relations & Corporate Development – [email protected]